CVS Health Corporation (NYSE:CVS) Given Average Rating of “Moderate Buy” by Brokerages

CVS Health Corporation (NYSE:CVS) has received an average recommendation of “Moderate Buy” from the twenty-five research firms that are presently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and twenty-one have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $101.28.

Several research analysts have recently issued reports on CVS shares. HSBC upped their price objective on CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Tuesday, May 5th. Sanford C. Bernstein boosted their target price on shares of CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Barclays boosted their price objective on shares of CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a research report on Thursday, June 11th. Finally, Royal Bank Of Canada upped their price target on CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th.

CVS Health Trading Up 0.0%

NYSE CVS opened at $104.74 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health has a twelve month low of $58.50 and a twelve month high of $106.15. The company has a market cap of $133.64 billion, a price-to-earnings ratio of 46.14, a price-to-earnings-growth ratio of 1.03 and a beta of 0.61. The business’s fifty day moving average is $94.56 and its 200 day moving average is $83.29.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts expect that CVS Health will post 7.44 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Tilak Mandadi sold 69,551 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This represents a 24.20% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by insiders.

Hedge Funds Weigh In On CVS Health

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its holdings in CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares during the period. Swiss RE Ltd. acquired a new position in shares of CVS Health in the 4th quarter valued at about $26,000. Sankala Group LLC acquired a new position in shares of CVS Health in the 4th quarter valued at about $28,000. Global Trust Asset Management LLC boosted its position in shares of CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after purchasing an additional 300 shares in the last quarter. Finally, Mcguire Capital Advisors Inc. acquired a new stake in CVS Health during the fourth quarter worth approximately $28,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.